John Neoptolemos - Selected Publications#

1. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11; 389 (10073): 1011-1024. Part of cancer guidelines, world-wide. Citations = 454.

2. Greenhalf W, Ghaneh P, *Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW; European Study Group for Pancreatic Cancer. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 Trial. Journal of the National Cancer Institute. 2014 Jan 1;106(1):djt347. doi: 10.1093/jnci/djt347. [*Corresponding author]. PMID: 24301456. Establsih biomarker for efficacy of adjuvant gemitabine chemotherapy in pancreatic cancer. Citations =184.

3. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10): 1073-81. Part of cancer guidelines, world-wide. Part of cancer guidelines, world-wide. Citations = 1025.

4 . Raraty MGT, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, Sutton R, Neoptolemos JP. Minimal Access Retroperitoneal Pancreatic Necrosectomy – Improvement in morbidity and mortality with a less invasive approach. Annals of Surgery2010; 251(5):787-93. Dramatic reduction in mortality from pancreatic necrosis using minimally invasive surgery. Citations = 270.

5. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27(33): 5513-5518. Part of cancer guidelines, world-wide. Citations = 760.

6. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP for the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC), Kress R, Sina-Frey M, Rieder H, Hahn SA, Bartsch DK, for the German national Case Collecton for Familial Pancreatic Cancer (FaPaCa). Anticipation in familial pancreatic cancer. Gut 2006; 55:252-258. Description of familial pancreatic cancer Europe. Contribution to UK NICE guidelines. Citations = 122.

7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW for the members of the European Study Group for Pancreatic Cancer (ESPAC). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine 2004; 350(12):1200-1210. Part of cancer guidelines, world-wide. Citations = 2,435.

8. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP; European Registry of Hereditary Pancreatitis and Pnacreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology 2004; 2(3):252–261. Part of guidelines, world-wide. Citations = 455.

9. Threadgold J, Greenhalf W, Ellis I, Howes N, Lerch MM, Jansen J, Charnley R, Laugier R, Frulloni L, Attila GO, Delhaye M, Ihse I, Schaffalitzky de Muchadell OB, Andrén-Sandberg Å, Imrie CW, Martinek J, Gress TM, Mountford R, Whitcomb D, Neoptolemos JP. The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut 2002; 50: 675-681.Demsostration that SPINK1 is a genetic rsisk factor in pancreatitis - not a Mendelian determinant of disease. Part of guidelines, world-wide. Citations = 228.

10. Neoptolemos JP, Dunn JA, Moffitt DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H and Büchler M, for the members of the European Study Group for Pancreatic Cancer (ESPAC). ESPAC-1: A European, Randomized Controlled Study of Adjuvant Chemoradiation and Chemotherapy in Resectable Pancreatic Cancer. Lancet 2001; 358: 1576-85. Part of cancer guidelines, world-wide. Citations = 997.